BioCentury | Oct 7, 2020
Tools & Techniques

Doudna and Charpentier, CRISPR pioneers behind a spate of gene editing companies, awarded Nobel Prize

Jennifer Doudna and Emmanuelle Charpentier have won the 2020 Nobel Prize in Chemistry eight years after their joint discovery that the CRISPR-Cas9 bacterial immune defense system can be harnessed...
BioCentury | Jul 25, 2020

Preclinical IPOs attracting big money, but yet to see exponential growth of clinical peers

An analysis of preclinical IPO performance since the window opened eight years ago shows the companies have done about as well as their clinical peers. What’s missing are standout examples of explosive growth, though those...
BioCentury | Jul 10, 2020
Product Development

Data Bytes: Cellectis remains active in allogeneic pipeline for multiple myeloma despite clinical hold

Even with the clinical hold on its Phase I trial of UCARTCS1A, Cellectis remains one of the most active companies developing allogeneic cell therapies for multiple myeloma, with another program -- ALLO-715 -- in Phase...
BioCentury | Jun 13, 2020
Product Development

Additional durability data build confidence for gene editing, gene therapies in hemoglobinopathies

It’s all about durability for gene therapies and gene editing treatments in hemoglobinopathies, and new data suggest programs from partners CRISPR Therapeutics and Vertex as well as bluebird are on track to deliver. In addition...
BioCentury | May 16, 2020
Product Development

Daily Chart: ide-cel’s challengers in the BCMA pipeline

Wednesday’s refusal-to-file letter for idecabtagene vicleucel slows the cell therapy from bluebird bio Inc. and Bristol Myers Squibb Co. in the race to market a product targeting BCMA to treat multiple myeloma (see “Refusal-to-File Letter...
BioCentury | Feb 29, 2020
Product Development

CRISPR-based diagnostics are poised to make an early debut amid COVID-19 outbreak

CRISPR could see its first direct application to human health much earlier than expected as the COVID-19 outbreak accelerates development timelines for CRISPR-based diagnostics. Diagnostic testing for COVID-19 is currently conducted with real-time PCR tests...
BioCentury | Jan 11, 2020

Why buysiders say 2020 could be the year of the CNS

A pair of CNS approvals in the final days of 2019 has only added to the growing momentum buysiders were already tracking for 2020 in the once neglected disease area. Positive regulatory signals are converging...
BioCentury | Dec 11, 2019
Tools & Techniques

Editas shows better gene editing using Cas9 alternative for sickle cell, thalassemia

Editas is using an alternative to Cas9 to develop a differentiated sickle cell and β thalassemia CRISPR gene therapy. Preclinical data presented Monday at ASH suggest that ex vivo gene editing could be more effective...
BioCentury | Dec 6, 2019
Targets & Mechanisms

Bispecifics and allogeneics steal the spotlight from autologous CAR Ts

Standing out at this year's ASH meeting is a pair of growing threats to first-generation CAR T cell therapies: bispecific antibodies and allogeneic cell therapies. Gone are the days when autologous CAR Ts were the...
BioCentury | Nov 22, 2019
Financial News

Follow-on roundup: Karuna, CRISPR, Molecular Therapeutics, OptiNose

Since market close on Wednesday, Karuna, CRISPR Therapeutics, Molecular Therapeutics and OptiNose have raised an aggregate of more than $600 million in follow-ons. Karuna Therapeutics Inc. (NASDAQ:KRTX) raised $250 million late Wednesday through the sale...
Items per page:
1 - 10 of 128